US-based Eli Lilly has planned to continue its focus on innovation-driven products, instead of opening up to opportunities in off-patent generic drugs, being tapped by its larger competitors like GSK and Pfizer.
A sampling of ideas from the next generation of consumers -- and entrepreneurs.
United States' Food and Drug Administration has granted approval to Ranbaxy Laboratories Ltd to manufacture and market 40 mg capsules of Fluoxetine, a drug used in treatment of obsessive-compulsive disorders.\n\n
Eli Lily, Sanofi Aventis, Bristol Myers approach chemicals ministry.
If you get stuck with business-as-usual, you get left behind.
The Supreme Court will decide whether domestic companies must deduct tax at source on salaries paid to their expatriate staff and if tax can be levied on these employees on wages given abroad by foreign joint venture partners of the Indian firms.
Leading insulin makers on Friday slashed the rates of human insulin by about 40 per cent, a move which will provide a big relief to diabetic patients.
Drugmaker Dr Reddy's Laboratories has filed an application with the US Food and Drug Administration to market a generic form of Eli Lilly's schizophrenia drug Olanzapine in the US
'It is not just the US and European opportunity, but it is a huge global opportunity.'
However, Cipla was very clear it does not want to get into vaccine manufacturing.
'I want everybody to be given the same treatment as your president because I feel great. I feel like perfect'
Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.
'However, we have seen weakness in our active pharmaceutical ingredients business.'
Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.
An Internet sensation, Lilly Singh worked her charm on the red carpet.
Drysdale wins close single sculls gold Also, check out late gold medal winners from Day 7...
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances